share_log

Revance Therapeutics Analyst Ratings

Revance Therapeutics Analyst Ratings

復活治療分析師評級
Benzinga Analyst Ratings ·  2023/01/24 09:28
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/24/2023 -22.41% Morgan Stanley $25 → $26 Maintains Equal-Weight
01/10/2023 13.4% Needham $35 → $38 Maintains Buy
11/16/2022 10.41% Barclays $35 → $37 Maintains Overweight
11/09/2022 -25.4% Morgan Stanley $27 → $25 Maintains Equal-Weight
10/11/2022 -19.43% Morgan Stanley → $27 Initiates Coverage On → Equal-Weight
09/22/2022 -1.52% Goldman Sachs → $33 Initiates Coverage On → Buy
09/09/2022 -10.47% Mizuho $26 → $30 Maintains Buy
09/09/2022 4.45% Barclays $22 → $35 Maintains Overweight
09/09/2022 -13.46% HC Wainwright & Co. $25 → $29 Maintains Buy
09/09/2022 4.45% Needham $25 → $35 Maintains Buy
08/25/2022 -28.38% Wells Fargo $17 → $24 Maintains Equal-Weight
10/26/2021 -34.35% Barclays $33 → $22 Maintains Overweight
10/25/2021 -49.27% Wells Fargo → $17 Downgrades Overweight → Equal-Weight
10/18/2021 -25.4% Needham $45 → $25 Maintains Buy
10/18/2021 -46.28% HC Wainwright & Co. $26 → $18 Maintains Buy
10/13/2021 -22.41% HC Wainwright & Co. $35 → $26 Maintains Buy
08/06/2021 -1.52% Barclays $32 → $33 Maintains Overweight
02/23/2021 4.45% HC Wainwright & Co. $33 → $35 Maintains Buy
01/08/2021 34.29% Needham $42 → $45 Maintains Buy
10/15/2020 25.34% Needham $36 → $42 Maintains Buy
04/16/2020 -7.49% Stifel $35 → $31 Maintains Buy
04/01/2020 4.45% Mizuho $39 → $35 Maintains Buy
03/27/2020 -28.38% HC Wainwright & Co. $28 → $24 Reiterates → Buy
03/23/2020 -55.24% Goldman Sachs $32 → $15 Downgrades Buy → Neutral
02/25/2020 19.37% Piper Sandler $37 → $40 Reiterates → Overweight
02/25/2020 7.43% Needham $32 → $36 Maintains Buy
02/18/2020 10.41% Piper Sandler $38 → $37 Maintains Overweight
01/23/2020 16.38% Mizuho $34 → $39 Maintains Buy
12/02/2019 -25.4% Goldman Sachs → $25 Initiates Coverage On → Buy
10/30/2019 -40.32% Wells Fargo $12.5 → $20 Upgrades Market Perform → Outperform
06/11/2019 -16.44% Barclays → $28 Initiates Coverage On → Overweight
02/15/2019 — Wells Fargo Initiates Coverage On → Market Perform
02/14/2019 -25.4% HC Wainwright & Co. → $25 Initiates Coverage On → Buy
01/29/2019 49.21% Stifel → $50 Initiates Coverage On → Buy
11/16/2018 22.35% Guggenheim → $41 Upgrades Neutral → Buy
09/17/2018 — JMP Securities Downgrades Market Outperform → Market Perform
03/05/2018 79.05% Goldman Sachs → $60 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/24/2023 -22.41% 摩根士丹利 $25 → $26 維護 等重
01/10/2023 13.4% 李約瑟 $35 → $38 維護 買
11/16/2022 10.41% 巴克萊 $35 → $37 維護 超重
11/09/2022 -25.4% 摩根士丹利 $27 → $25 維護 等重
10/11/2022 -19.43% 摩根士丹利 → $27 開始承保 →等重
09/22/2022 -1.52% 高盛 → $33 開始承保 →購買
09/09/2022 -10.47% 瑞穗 $26 → $30 維護 買
09/09/2022 4.45% 巴克萊 $22 → $35 維護 超重
09/09/2022 -13.46% HC Wainwright公司 $25 → $29 維護 買
09/09/2022 4.45% 李約瑟 $25 → $35 維護 買
08/25/2022 -28.38% 富國銀行 $17 → $24 維護 等重
10/26/2021 -34.35% 巴克萊 $33 → $22 維護 超重
10/25/2021 -49.27% 富國銀行 → $17 評級下調 超重→等重
10/18/2021 -25.4% 李約瑟 $45 → $25 維護 買
10/18/2021 -46.28% HC Wainwright公司 $26 → $18 維護 買
10/13/2021 -22.41% HC Wainwright公司 $35 → $26 維護 買
08/06/2021 -1.52% 巴克萊 $32 → $33 維護 超重
02/23/2021 4.45% HC Wainwright公司 $33 → $35 維護 買
01/08/2021 34.29% 李約瑟 $42 → $45 維護 買
10/15/2020 25.34% 李約瑟 $36 → $42 維護 買
04/16/2020 -7.49% Stifel $35 → $31 維護 買
04/01/2020 4.45% 瑞穗 $39 → $35 維護 買
03/27/2020 -28.38% HC Wainwright公司 $28 → $24 重申 →購買
03/23/2020 -55.24% 高盛 $32 → $15 評級下調 購買→中性
02/25/2020 19.37% 派珀·桑德勒 $37 → $40 重申 →超重
02/25/2020 7.43% 李約瑟 $32 → $36 維護 買
02/18/2020 10.41% 派珀·桑德勒 $38 → $37 維護 超重
01/23/2020 16.38% 瑞穗 $34 → $39 維護 買
12/02/2019 -25.4% 高盛 → $25 開始承保 →購買
10/30/2019 -40.32% 富國銀行 $12.5 → $20 升級 市場表現優於→
06/11/2019 -16.44% 巴克萊 → $28 開始承保 →超重
02/15/2019 — 富國銀行 開始承保 →市場表現
02/14/2019 -25.4% HC Wainwright公司 → $25 開始承保 →購買
01/29/2019 49.21% Stifel → $50 開始承保 →購買
11/16/2018 22.35% 古根海姆 → $41 升級 中性→購買
09/17/2018 — JMP證券 評級下調 市場表現優於→市場表現
03/05/2018 79.05% 高盛 → $60 開始承保 →購買

What is the target price for Revance Therapeutics (RVNC)?

Revance Treeutics(RVNC)的目標價格是多少？

There is no price target for Revance Therapeutics

Revance Treeutics沒有價格目標

What is the most recent analyst rating for Revance Therapeutics (RVNC)?

Revance Treeutics(RVNC)的最新分析師評級是多少？

There is no analyst for Revance Therapeutics

Revance Treeutics沒有分析師

When is the next analyst rating going to be posted or updated for Revance Therapeutics (RVNC)?

Revance Treeutics(RVNC)的下一次分析師評級將於何時發佈或更新？

There is no next analyst rating for Revance Therapeutics

Revance Treeutics沒有下一個分析師評級

Is the Analyst Rating Revance Therapeutics (RVNC) correct?

分析師對Revance Treeutics(RVNC)的評級正確嗎？

There is no next analyst rating for Revance Therapeutics

Revance Treeutics沒有下一個分析師評級

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論